Minapharm Pharmaceuticals results, Q3 2025
Net profit, assets, equity and cash flow for Q3 2025, against the same period a year earlier, from the published financial statements.
Net profit16.85 millionEGP · −73.3% vs the same period a year earlier
Operating cash flow-68.13 millionEGP · +10.4% vs the same period a year earlier
In short
- Minapharm Pharmaceuticals's net profit for Q3 2025 was about 16.85 million EGP, down −73.3% from 63.19 million EGP in Q3 2024.
- Operating cash flow for Q3 2025 was negative at 68.13 million EGP.
Key lines against the same period a year earlier
This periodQ3 2024Change
Net profit16.85 million63.19 million−73.3%
Gross profit559 million636 million−12.1%
Total assets—11.83 billion—
Total liabilities—7.38 billion—
Shareholders' equity—4.45 billion—
Total liabilities and equity—11.83 billion—
Operating cash flow-68.13 million-76.01 million+10.4%
Investing cash flow-224 million96.95 million−331.5%
Financing cash flow1.16 billion-262 million+542.4%
Net change in cash869 million-242 million+459.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Minapharm Pharmaceuticals's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy